Goldman Sachs Group Inc. is considering sweetening the terms on $1.73 billion of leveraged loans tied to chemical maker Arclin Inc.’s acquisition of DuPont de Nemours Inc.’s Aramids business.
Goldman Sachs Group Inc. is considering sweetening the terms on $1.73 billion of leveraged loans tied to chemical maker Arclin Inc.’s acquisition of DuPont de Nemours Inc.’s Aramids business.
The Goldman Sachs headquarters in New York, US, on Friday, July 11, 2025. Goldman Sachs Group Inc. is scheduled to release earnings figures on July 16. Photographer: Gabby Jones/Bloomberg
Anmelden
